Kiniksa Pharmaceuticals International, plc (KNSA) Stock Grade

About Kiniksa Pharmaceuticals International, plc's fundamentals

Kiniksa Pharmaceuticals is a biopharmaceutical company with a market capitalization of $3.1 billion that is experiencing significant growth, with revenue increasing 60.1% year-over-year. The company maintains a net profit margin of 8.7%, though its return on equity stands at a modest 10.4%, and it does not currently pay a dividend. The stock trades at a P/E ratio of 51.9, which is elevated relative to the broader market, reflecting investor expectations for a high-growth pharmaceutical company.